Friday, 22 January 2021

Neuberg Diagnostics appoints A Ganesan as Group Vice Chairman

08 December 2020 | News

In his new role, Ganesan will continue to play a key role and be actively involved in the business expansions

Neuberg Diagnostics has announced the appointment of A Ganesan as the Group Vice Chairman of Neuberg Diagnostics. In his new role, Ganesan will continue to play a key role and be actively involved in the business expansions.

Ganesan is a Chartered Accountant with over 33 years experience in Assurance and Advisory practice and also a veteran in healthcare field having handled in the past M&A deals for Metropolis Group, Trivitron Group and  Maxivision Eye Hospitals. At Neuberg, in his previous role as Director of Finance, his broad vision and pro-active efforts have enabled the company to win several accolades and making it one of the top 4 diagnostics companies in the country.

Dr GSK Velu, Chairman and MD, Neuberg Diagnostics said, “Ganesan brings strong domain knowledge with breadth of business experience which currently is very critical for Neuberg. It has been 20 years since we have been working closely. Given his exceptional ability to drive businesses, we are sure that in this new role, he will enable the Group to step through our next phase of growth and market leadership.”

Ganesan said, “I am honoured to lead our company which currently is in its expansion phase. I will endeavour to ensure we continue our journey on stated growth path. I look forward to working closely with distinguished leadership.”  

Ganesan is a Chemistry graduate from Madras University and a fellow member of The Institute of Chartered Accountants of India (ICAI). He is presently on the Board of Trivitron Healthcare Private Ltd, Kauvery Hospital and Maxivision Eye Hospitals Private Ltd. He was also a Director on the Board of Metropolis Healthcare Ltd, which he had relinquished in 2015.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account






Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls